Novavax (NASDAQ:NVAX) announces
that it has identified a coronavirus vaccine candidate, a stable
prefusion protein that it has named NVX-CoV2373, that will also
incorporate its Matrix-M adjuvant.
A Phase 1 study in ~130 healthy volunteers will
launch in mid-May. Safety and preliminary immunogenicity data should be
available in July.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.